LUMASON Drug Patent Profile
✉ Email this page to a colleague
When do Lumason patents expire, and when can generic versions of Lumason launch?
Lumason is a drug marketed by Bracco and is included in one NDA. There are three patents protecting this drug.
This drug has thirty-seven patent family members in twelve countries.
The generic ingredient in LUMASON is sulfur hexafluoride lipid-type a microspheres. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sulfur hexafluoride lipid-type a microspheres profile page.
DrugPatentWatch® Generic Entry Outlook for Lumason
Lumason was eligible for patent challenges on October 10, 2018.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be July 6, 2038. This may change due to patent challenges or generic licensing.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for LUMASON?
- What are the global sales for LUMASON?
- What is Average Wholesale Price for LUMASON?
Summary for LUMASON
| International Patents: | 37 |
| US Patents: | 3 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 34 |
| Clinical Trials: | 31 |
| Drug Prices: | Drug price information for LUMASON |
| What excipients (inactive ingredients) are in LUMASON? | LUMASON excipients list |
| DailyMed Link: | LUMASON at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for LUMASON
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for LUMASON
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Milton S. Hershey Medical Center | Early Phase 1 |
| Mayo Clinic | Phase 2 |
| Thomas Jefferson University | Phase 2 |
Pharmacology for LUMASON
| Drug Class | Contrast Agent for Ultrasound Imaging |
| Mechanism of Action | Ultrasound Contrast Activity |
US Patents and Regulatory Information for LUMASON
LUMASON is protected by five US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of LUMASON is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting LUMASON
Freeze-dried formulation for gas-filled microvesicles
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Freeze-dried formulation for gas-filled microvesicles
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE IN ADULT AND PEDIATRIC PATIENTS WITH SUBOPTIMAL ECHOCARDIOGRAMS TO OPACIFY THE LEFT VENTRICULAR CHAMBER AND TO IMPROVE THE DELINEATION OF THE LEFT VENTRICULAR ENDOCARDIAL BORDER
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE IN ULTRASONOGRAPHY OF THE URINARY TRACT IN PEDIATRIC PATIENTS FOR THE EVALUATION OF SUSPECTED OR KNOWN VESICOURETERAL REFLUX
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: USE WITH ULTRASOUND OF THE LIVER IN ADULT AND PEDIATRIC PATIENTS TO CHARACTERIZE FOCAL LIVER LESIONS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bracco | LUMASON | sulfur hexafluoride lipid-type a microspheres | FOR SUSPENSION;INTRAVENOUS | 203684-001 | Oct 15, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Bracco | LUMASON | sulfur hexafluoride lipid-type a microspheres | FOR SUSPENSION;INTRAVENOUS | 203684-001 | Oct 15, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Bracco | LUMASON | sulfur hexafluoride lipid-type a microspheres | FOR SUSPENSION;INTRAVENOUS | 203684-001 | Oct 15, 2014 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for LUMASON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Bracco | LUMASON | sulfur hexafluoride lipid-type a microspheres | FOR SUSPENSION;INTRAVENOUS | 203684-001 | Oct 15, 2014 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for LUMASON
When does loss-of-exclusivity occur for LUMASON?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 19298652
Patent: Freeze-dried formulation for gas-filled microvesicles
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2020022883
Patent: formulação liofilizada para microvesículas preenchidas com gás
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 98380
Patent: FORMULATION LYOPHILISEE POUR MICROVESICULES REMPLIES DE GAZ (FREEZE-DRIED FORMULATION FOR GAS-FILLED MICROVESICLES)
Estimated Expiration: ⤷ Sign Up
China
Patent: 2165959
Patent: 用于充气微泡的冻干制剂 (FREEZE-DRIED FORMULATION FOR GAS-FILLED MICROVESICLES)
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 17777
Patent: FORMULATION LYOPHILISÉE POUR MICROVÉSICULES REMPLIES DE GAZ (FREEZE-DRIED FORMULATION FOR GAS-FILLED MICROVESICLES)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 28299
Estimated Expiration: ⤷ Sign Up
Patent: 21529730
Patent: ガスが充填された微小胞のための凍結乾燥製剤
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 20012604
Patent: FORMULACION CONGELADA PARA MICROVESICULAS LLENAS DE GAS. (FREEZE-DRIED FORMULATION FOR GAS-FILLED MICROVESICLES.)
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 202010539R
Patent: FREEZE-DRIED FORMULATION FOR GAS-FILLED MICROVESICLES
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2556398
Estimated Expiration: ⤷ Sign Up
Patent: 210029712
Patent: 기체-충전 미세소포를 위한 동결-건조 제제
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering LUMASON around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| China | 1056634 | ⤷ Sign Up | |
| Canada | 2056371 | SUSPENSIONS DE MICROBULLES STABLES INJECTABLES DANS DES ORGANISMES VIVANTS (STABLE MICROBUBBLES SUSPENSIONS INJECTABLE INTO LIVING ORGANISMS) | ⤷ Sign Up |
| South Korea | 960002184 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for LUMASON
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0619743 | SPC/GB01/043 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: SULPHUR HEXAFLUORIDE; REGISTERED: UK EU/1/01/177/001 20010326; UK EU/1/01/177/002 20010326 |
| 1345920 | SPC/GB14/018 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: MACITENTAN, WHICH IS N-(5-(4-BROMOPHENYL)-6-(2((5-BROMOPYRIMIDIN-2-YL)OXY)ETHOXY)PYRIMIDIN-4-YL)-N'-PROPYLSULFURIC DIAMIDE; REGISTERED: UK EU/1/13/893 20131220 |
| 0619743 | 300061 | Netherlands | ⤷ Sign Up | PRODUCT NAME: ZWAVELHEXAFLUORIDE; REGISTRATION NO/DATE: EU/1/01/177/001 20010326 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
